BIIB-061

N/A

Report date: 2023/06/02 20:00:31

NME

Base Information

Drug NameBIIB-061

Drug Alias NameBIIB-061

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionMyelin proteins stimulants

TargetsMyelin proteins

Therapy Area/IndicationsMultiple Sclerosis

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesBiogen Inc

China Registration ClassN/A

Active CompaniesN/A

Inactive CompaniesBiogen Inc

Active IndicationsN/A

Inactive IndicationsMultiple Sclerosis

ATC CodeN/A